Outlook Therapeutics Inc (OTLK)
followers
·
Follow
Sector: | HEALTH CARE |
Industry: | PHARMACEUTICALS |
SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
CEO: | C. Russell Trenary |
Employees: | 20 |
Web site: | outlooktherapeutics.com |
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830
6096193990
|
Date | Ratio |
---|---|
2019-03-18 | 1:8 |
2024-03-14 | 1:20 |
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|
Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Please log in first to see chart